Evidence map›Paper›PMID 40554782›Full record

ArticleJMIR research protocols2025

The First 6 Years' Experiences of a National Centralized Offspring Surveillance Setting for Dutch Children Prenatally Exposed to Maternal Cancer to Inform Future International Practice: Protocol for a Demographic Review of Referred Families and Key Lessons Learned.

Evangeline A Huis In 't Veld, Anouk M Kruse, Emma J Verwaaijen, Sterre C Huizer, Elisabeth M van Dijk-Lokkart, Christianne Lok, Maaike Kuethe, Frederic Amant, Mathilde M A van Gerwen, Martine van Grotel and 1 more

Abstract read
In one paragraph

Article in JMIR research protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Evangeline A Huis In 't VeldCenter for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-6891-2255
Anouk M KrusePrincess Máxima Center, Utrecht, The Netherlands.ORCID 0009-0001-3980-8619
Emma J VerwaaijenPrincess Máxima Center, Utrecht, The Netherlands.ORCID 0000-0003-1350-3363
Sterre C HuizerCenter for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0009-0003-6695-8334
Elisabeth M van Dijk-LokkartDepartment of Child & Adolescent Psychiatry and Psychosocial Care, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-3441-5135
Christianne LokCenter for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0001-8693-7299
Maaike KuetheStichting Ster(k), Den Haag, The Netherlands.ORCID 0009-0004-3966-1073
Frederic AmantCenter for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-5452-4905
Mathilde M A van GerwenCenter for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0001-5564-8873
Martine van GrotelPrincess Máxima Center, Utrecht, The Netherlands.ORCID 0000-0002-8849-8573
Marry M van den Heuvel-EibrinkPrincess Máxima Center, Utrecht, The Netherlands.ORCID 0000-0002-7760-879X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer during pregnancy is a rare and significant life-changing event affecting approximately 1 in 1000-2000 pregnancies. With increasing maternal age and broader application of prenatal screening programs such as the Dutch Non-Invasive Prenatal Testing, incidental detection of maternal cancer is becoming more frequent. Advancements in safe treatment options during pregnancy, supported by the International Network on Cancer Infertility and Pregnancy (INCIP), have led to fewer pregnancy terminations. Consequently, more children are exposed to chemotherapy and other cancer treatments in utero. While short-term safety has been demonstrated for many oncological agents, long-term side effects including physical, neuromotor, neurocognitive, and psychosocial impacts on offspring and their families after delivery are still being assessed. Standard settings for surveillance and care of offspring and their families have, however, never been described.

objectiveGiven the importance of expertise in assessing the long-term outcomes of children, the Netherlands established the national centralized Cancer in Pregnancy (CIP) offspring outpatient clinic in 2018, which functions as a standard-of-care surveillance clinic and contributes data to the INCIP registry. Here we provide a demographic overview of referred families and to share (logistic) experiences with the national, centralized, multidisciplinary, and standardized long-term surveillance program for all Dutch children with in utero exposure to maternal cancer and its treatment.

methodsThe CIP offspring outpatient clinic is located at the Princess Máxima Center for Pediatric Oncology and provides surveillance from infancy until 18 years of age. The, relatively small dedicated team, comprising pediatric oncologists, physiotherapists, and a psychological expert, offers a 1-day, multidisciplinary assessment, including physical examinations, neuromotor tests, cardiac monitoring (for anthracycline exposure), renal and auditory screening (for platinum agents), neurocognitive testing, and psychosocial evaluation. Surveillance is aligned with international INCIP guidelines.

resultsFrom May 2018 to 2024, a total of 226 children (from 221 mothers) have been referred to the CIP offspring outpatient clinic, with 465 follow-up visits completed. The most common maternal cancer types were breast, gynecological, and hematological malignancies. Most women (58%) received chemotherapy during pregnancy; 11% of them had surgery only, 3% underwent radiotherapy, 3% underwent immunotherapy, 16% received a combination of treatment modalities, and 8% did not undergo treatment during pregnancy. Anthracyclines were the most commonly used agents. Median gestational age at delivery was 37.3 weeks. Fourteen percent of the mothers died shortly after delivery, underscoring the emotional and logistical challenges for families.

conclusionsThe CIP offspring outpatient clinic provides a unique, structured approach to long-term surveillance for in utero-exposed children, which enables early detection of potential late effects and provides comprehensive family support. By sharing knowledge and experiences from the unique setting of this national centralized CIP offspring outpatient clinic, this initiative may inspire other countries in developing similar translational facilities to support affected families and improve care worldwide. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/71612.

Indexed as

NeoplasmsPregnancy Complications, NeoplasticPrenatal Exposure Delayed EffectsAdolescentAdultChildChild, PreschoolFemaleHumansInfantInfant, NewbornMaleNetherlandsPregnancycancerexposure in utero, toxic effectsoffspringoutpatient clinicsurveillancetreatment

Identifiers

PMID40554782
PMCPMC12238779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.